Printer Friendly

RESEARCH ON THE USE OF ELECTROPORATION TO ENHANCE TRANSDERMAL DRUG DELIVERY IS PUBLISHED

 REDWOOD CITY, Calif., Nov. 16 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN) and the Massachusetts Institute of Technology announced the publication of a research paper in the prestigious Proceedings of the National Academy of Sciences in the Nov. 15 issue.
 The paper, entitled, "Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery," was authored by Mark Praunitz, Vanu Bose, Robert Langer and James Weaver from M.I.T. Four key findings are reported in this paper. First, the application of short electrical pulses (electroporation) increases the delivery of molecules (up to 1,100 molecular weight) through the skin by up to 10,000-fold over passive delivery by creating temporary and reversible transport pathways through the skin. Second, electroporation showed up to at least a 1,000-fold drug delivery enhancement compared to iontophoresis (a steady electrical charge). Third, the use of electroporation results in the rapid onset of transdermal delivery. Fourth, electroporation has the capability for programmed delivery of molecules, that is, differing levels of drugs at different times. These results may have an important impact on the future of transdermal drug delivery.
 "As a leader in advanced drug delivery, Cygnus is committed to advancing the frontiers of drug delivery technology," stated Dr. Gary Cleary, chairman and chief technical officer. "Working with leading edge academic researchers like professors Langer and Weaver keeps Cygnus on the forefront of breakthrough technologies for drug delivery."
 Langer, Weaver and Powell are inventors on a patent issued to M.I.T. on the use of electroporation for the transport of molecules across tissues. Cygnus has exclusive worldwide rights to that patent.
 Cygnus is a leader in advanced drug delivery systems. The company's primary focus is in the hormone replacement, smoking cessation, consumer products and glucose monitoring markets. Cygnus has more than a dozen products in various stages of development, including one product in the market (Nicotrol TM) and two in Phase III clinical trials.
 -0- 11/16/93
 /CONTACT: Craig Carlson, vice president of corporate communications for Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems ST: California IN: MTC SU:

PK-LW -- SJ007 -- 5215 11/16/93 16:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:353
Previous Article:PUBLIC OFFERING OF ALLIED LIFE FINANCIAL CORPORATION COMMON STOCK PRICED AT $12.00 PER SHARE
Next Article:LG&E ENERGY CORP. TO REALIGN BUSINESSES IN MOVE TO PREPARE FOR ENERGY INDUSTRY CHANGE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters